Dovetail Genomics launches epigenetics society

By The Science Advisory Board staff writers

November 10, 2021 -- Dovetail Genomics has formed what it is calling the Boston Epigenetics Society, a group that will meet four times annually to support epigenetics and epitranscriptomics research and forge relationships between academics and scientists.

The society's first meeting will be held virtually on November 16 from 10-11 a.m. Eastern time. It will feature David Sinclair, PhD, professor of genetics and co-director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School in Boston and Robert Copeland, president, CEO, and co-founder of Accent Therapeutics.

If you like this content, please share it with a colleague!

Related Reading

Dovetail Genomics expands epigenetics offerings
Dovetail Genomics is expanding its epigenetics offerings in the areas of bioinformatics and target enrichment as an add-on to the company's Micro-C projects.

Dovetail launches 2 new Hi-C-targeted enrichment panels
Dovetail Genomics has launched its new line of capture Hi-C technology including two targeted enrichment panels, the Dovetail Human Pan Promoter Enrichment...